Justia Patents Opinion Summaries

USR sued Apple for infringement of patents otherwise directed to similar technology, securing electronic payment transactions. The patents “address the need for technology that allows consumers to conveniently make payment-card [e.g., credit card] transactions without a magnetic-stripe reader and with a high degree of security.”The district court found all claims of four asserted patents ineligible under 35 U.S.C. 101. The Federal Circuit affirmed. All claims of the asserted patents are directed to an abstract idea and contain no additional elements that transform them into a patent-eligible application of the abstract idea. Applying the Supreme Court’s “Alice” analysis, the court stated that sending data to a third party as opposed to the merchant is an abstract idea and cannot serve as an inventive concept, as is authenticating a user using conventional tools and generating and transmitting that authentication—without “improv[ing] any underlying technology.” Nothing in the claims is directed to a new authentication technique; rather, the claims are directed to combining longstanding, known authentication techniques to yield expected additional amounts of security. View "Universal Secure Registry LLC v. Apple Inc." on Justia Law

T cells, white blood cells that contribute to the immune response, have naturally occurring receptors on their surfaces that facilitate their attack on target cells (such as cancer cells) by recognizing and binding an antigen, i.e., a structure on a target cell’s surface. Chimeric antigen receptor (CAR) T-cell therapy involves isolating a patient’s T cells; reprogramming those T cells to produce a specific, targeted receptor (a CAR) on each T cell’s surface; and infusing the patient with the reprogrammed cells. Juno’s patent relates to a nucleic acid polymer encoding a three-part CAR for a T cell. It claims priority to a provisional application filed in 2002, at “the birth of the CART field.” Kite’s YESCARTA® is a “therapy in which a patient’s T cells are engineered to express a [CAR] to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells.”Juno sued, alleging infringement. The district court held that the claims were not invalid for lack of written description or enablement, the patent’s certificate of correction was not invalid, and Juno was entitled to $1,200,322,551.50 in damages. The Federal Circuit reversed. No reasonable jury could find the patent’s written description sufficiently demonstrates that the inventors possessed the full scope of the claimed invention. View "Juno Therapeutics, Inc v. Kite Pharma, Inc." on Justia Law

MLC sued Micron for infringing certain claims of a patent, titled “Electrically Alterable Non-Volatile Memory with N-bits Per Cell,” describing methods of programming multi-level cells. The district court excluded certain opinions of MLC’s damages expert.On interlocutory appeal, the Federal Circuit affirmed orders precluding MLC’s damages expert from characterizing certain license agreements as reflecting a 0.25% royalty, opining on a reasonable royalty rate when MLC failed to produce key documents and information directed to its damages theory when requested prior to expert discovery, and opining on the royalty base and royalty rate where the expert failed to apportion for non-patented features. View "MLC Intellectual Property, LLC v. Micron Technology, Inc." on Justia Law

DET sued Google for infringing its “Tab Patents,” which are directed to systems and methods for displaying and navigating three-dimensional electronic spreadsheets by implementing user-customizable “notebook tabs” on the spreadsheet interface. In 2018, the Federal Circuit reversed a holding that the claims were patent ineligible. On remand, the district court granted Google summary judgment of noninfringement, premised on its construction of the term “three-dimensional spreadsheet” recited in the preamble of the asserted claims. The Federal Circuit affirmed, holding that the preamble is limiting and adopting the district court’s construction of that term. DET did not argue that the accused product infringes under the district court’s construction. View "Data Engine Technologies LLC v. Google LLC" on Justia Law

CommScope sued Dali, alleging infringement of five of CommScope’s patents relating to telecommunications technology. Dali counterclaimed, alleging CommScope infringed two of Dali’s patents also relating to telecommunications technology. One of Dali’s asserted patents, the 521 patent, is titled “System and Method for Digital Memorized Predistortion for Wireless Communication.” This technology generally relates to wireless communications with portable equipment and handsets, such as mobile phones. Such devices often include a power amplifier to boost the signal. However, amplification can cause unintended distortions to the signal. The 521 patent resolves this problem through the use of a feedback loop and lookup tables.The district court entered judgment on the jury’s verdict of infringement, no invalidity, and damages for both CommScope and Dali. The Federal Circuit reversed with respect to the 521 patent and otherwise affirmed without opinion. Substantial evidence does not support the jury’s finding that CommScope’s FlexWave infringes Dali’s 521 patent. Dali failed to present evidence proving that the FlexWave meets the district court’s construction of the claim term “switching a controller off.” View "CommScope Technologies LLC v. Dali Wireless, Inc." on Justia Law

Gamon’s patents each claim “[t]he ornamental design for a gravity feed dispenser display.” Gamon’s commercial embodiment of the claimed designs is called the iQ Maximizer gravity feed dispenser, In 2002-2009, Gamon sold about $31 million worth of iQ Maximizers to Campbell. In 2008, Campbell began purchasing similar gravity feed dispensers from Trinity. Gammon sued for infringement. In inter partes review, the Patent Trial and Appeal Board rejected claims of obviousness. The Federal Circuit reversed. Weighing all of the “Graham" factors, including the Board’s finding that, from the perspective of a designer of ordinary skill, prior art creates the same overall visual impression as the claimed designs and copying by Trinity of the claimed designs’ unique characteristics, the claimed designs would have been obvious over the prior art. View "Campbell Soup Co. v. Gamon Plus, Inc." on Justia Law

Hyatt is a prolific patent filer and litigant. In 1995, Hyatt filed “hundreds of extraordinarily lengthy and complex patent applications,” including the four at issue; he adopted an approach "that all but guaranteed indefinite prosecution delay” in an effort to submarine his patent applications and receive lengthy patent terms. The examination of these patents has cost the Patent and Trademark Office (PTO) millions of dollars. After adverse results regarding the patents at issue, Hyatt sued the PTO under 35 U.S.C. 145. The PTO moved to dismiss the actions for prosecution laches. The district court ordered the PTO to issue a patent covering some of the claims.While an appeal was pending, Hyatt sought attorney’s fees under the Equal Access to Justice Act as a “prevailing party” 28 U.S.C. 2412(b). The district court granted this motion in part. The Sixth Circuit vacated, holding that the PTO had carried its initial burden of demonstrating prosecution laches. The PTO sought reimbursement of its expert witness fees. Under 35 U.S.C. 145, “[a]ll the expenses of the proceedings shall be paid by the applicant.” The district court noted the American Rule presumption against fee-shifting and denied expert fees. The Federal Circuit vacated. Hyatt is not entitled to attorney’s fees under 28 U.S.C. 2412(b) and cannot be considered a prevailing party. The court affirmed the denial of expert fees because section 145 does not specifically and explicitly shift expert witness fees. View "Hyatt v. Hirshfeld" on Justia Law

The separate inter partes review (IPR) proceedings concerned the 688 patent, and the 229 patent, which have the same inventors and owner. Both are directed to controllers for games consoles. The Patent Board determined that nine claims of the 688 patent were unpatentable as anticipated by the Uy application; five other claims were not unpatentable as obvious over a claimed prior art reference (Burns article) in combination with other references because a copy of the Burns article that Valve relied on had not been authenticated. The 229 patent is directed to “[a] hand[-]held controller for a games console,” “wherein the controller further includes at least one additional control located on a back of the controller,” The Board determined that none of the claims of the 229 patent were unpatentable as anticipated by Uy because Uy did not teach “an elongate member” that “is inherently resilient and flexible,” and because Valve failed to show that a copy of the Burns article Valve relied on as a reference to show obviousness was prior art.The Federal Circuit reversed the determination that the Exhibit is not prior art and vacated the determination that five claims of the ’688 patent and multiple claims of the 229 patent were not shown to be unpatentable. The court remanded for the Board to consider Valve’s arguments that relied on the Exhibit as to those claims. The court affirmed that other of the patents were not unpatentable. View "Valve Corp. v. Ironburg Inventions Ltd." on Justia Law

Teva’s patents, directed to methods of using humanized antagonist antibodies that target calcitonin gene-related peptide (CGRP), a 37-amino acid peptide that is “a neurotransmitter in the central nervous system, and has been shown to be a potent vasodilator. Dilation of blood vessels was associated with and thought to exacerbate the pain symptoms of migraine. Lilly filed petitions for inter partes review (IPR).In three IPR proceedings, the Board issued a combined final written decision holding that the challenged claims in all three patents are unpatentable as they would have been obvious over various cited references and that a skilled artisan would have been motivated to combine the teachings of the prior art and would have had a reasonable expectation of successfully achieving the claimed invention. The Federal Circuit affirmed, rejecting Teva’s arguments that the Patent Trial and Appeal Board erred as a matter of law in its motivation to combine analysis by deviating from the motivation asserted by Lilly in its IPR petitions, that even under the motivation to combine that the Board did analyze, substantial evidence does not support the Board’s factual findings, and that the Board erred in its analysis of secondary considerations of nonobviousness View "Teva Pharmaceuticals International GmbH v. Eli Lily & Co." on Justia Law

Teva's patents are directed to methods of using humanized antagonist antibodies that target calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid peptide that is “a neurotransmitter in the central nervous system and has been shown to be a potent vasodilator in the periphery, where CGRP-containing neurons are closely associated with blood vessels. Dilation of blood vessels was associated with and thought to exacerbate the symptoms of migraine. The challenged patents describe “anti-CGRP antagonist antibodies and methods of using anti-CGRP antagonist antibodies for treating or preventing vasomotor symptoms, such as headaches, such as migraine.” Lilly asserted that each challenged claim would have been obvious over a combination of prior art references.The Patent Trial and Appeal Board first construed the claims, including the preambles and the term “effective amount,” then analyzed prior art, concluding that Lilly failed to prove that the challenged claims would have been obvious over the stated references. The Federal Circuit affirmed, rejecting arguments that the Board erred by reading a result into the constructions of the preambles and the term “effective amount,” which led to erroneously requiring Lilly to prove that a skilled artisan would have expected to achieve results that are unclaimed and that, even if the preambles are limiting and the claims require administration of an antibody with an expectation of results, the Board applied too high a standard in determining whether a skilled artisan would have had a reasonable expectation of success. View "Eli Lilly & Co. v. Teva Pharmaceuticals International GMBH" on Justia Law